Daily Cardiology Research Analysis
Analyzed 126 papers and selected 3 impactful papers.
Summary
Analyzed 126 papers and selected 3 impactful articles.
Selected Articles
1. Early Prediction of Heart Failure From Routine Cardiac CT Using Radiomic Phenotyping of Epicardial Fat.
In a multicenter cohort of 72,751 adults undergoing routine CCTA, an automated epicardial fat radiomic signature (FRP) predicted incident heart failure over 4–5 years and improved risk stratification beyond traditional factors and CAC. The fully automated pipeline extracted 1,655 features and used a harmonized survival autoencoder, with consistent performance in external validation.
Impact: Provides a scalable, opportunistic tool to anticipate heart failure years before onset using existing CCTA data, potentially enabling precision prevention.
Clinical Implications: Incorporating EAT radiomic profiling into routine CCTA reports could flag high-risk individuals for intensified prevention (e.g., cardiometabolic risk optimization, closer follow-up) before overt HF develops.
Key Findings
- Automated extraction of 1,655 EAT radiomic features from routine CCTA yielded a fat radiomic profile (FRP) linked to incident heart failure.
- In internal and external validation (median follow-up 5.1 and 4.0 years), FRP predicted new-onset HF beyond traditional risk factors and CAC.
- Modeling used a harmonized survival autoencoder and showed robust, reproducible performance across centers.
Methodological Strengths
- Very large, multicenter cohort with external validation
- Fully automated segmentation and standardized survival modeling
Limitations
- Observational design limits causal inference; residual confounding possible
- Clinical thresholds and deployment pathways for FRP require prospective testing
Future Directions: Prospective interventional studies to test whether FRP-guided prevention reduces HF incidence; evaluation across diverse populations and CT vendors; integration with EHRs for automated alerts.
BACKGROUND: Epicardial adipose tissue (EAT) is a metabolically active visceral fat depot that is both a sensor and a modulator of myocardial biology and changes its composition in response to paracrine signals from the myocardium. We hypothesized that radiomic characterization of EAT from routine coronary computed tomographic angiography (CCTA) can noninvasively capture this adverse remodeling and enable early heart failure (HF) risk stratification. OBJECTIVES: We sought to develop and externally validate a reproducibl
2. Cost-Effectiveness of ApoB, Non-HDL-C, and LDL-C Goals for Primary Prevention Lipid-Lowering Therapy.
Using a computer simulation informed by NHANES and published data, intensifying lipid-lowering to an apoB goal (<78.7 mg/dL) was cost-effective versus a non-HDL-C goal, with an ICER of $30,300/QALY. A non-HDL-C goal improved QALYs and reduced costs versus LDL-C. At a $120,000/QALY threshold, an apoB goal was optimal in 65% of probabilistic analyses.
Impact: Directly informs biomarker selection for primary prevention strategies and payor policy by quantifying value of apoB-based goals.
Clinical Implications: Clinicians and systems can prioritize apoB testing and targets to guide intensification (statins/ezetimibe) for primary prevention, anticipating population-level health gains at acceptable cost.
Key Findings
- Compared with a non-HDL-C goal, an apoB goal gained 1,324 QALYs with an incremental cost of $40.2 million, yielding an ICER of $30,300/QALY.
- Compared with an LDL-C goal, a non-HDL-C goal gained 965 QALYs and reduced costs by $2.1 million.
- At a $120,000/QALY willingness-to-pay threshold, apoB goals were optimal in 65% of probabilistic analyses; non-HDL-C was optimal in 25%.
Methodological Strengths
- Robust probabilistic and traditional sensitivity analyses with nationally representative inputs
- Clear decision thresholds and transparent ICER reporting
Limitations
- Model-based analysis depends on assumptions about treatment effects and costs
- Did not evaluate broader therapy classes (e.g., PCSK9 inhibitors) within the primary framework
Future Directions: Prospective implementation studies testing apoB-guided care pathways and real-world budget impact; extension to include novel agents and different health systems.
IMPORTANCE: Apolipoprotein B (apoB) is a superior marker of residual atherosclerotic cardiovascular disease risk in patients treated with lipid-lowering therapy (LLT) compared with low-density lipoprotein cholesterol (LDL-C) and non-high-density lipoprotein cholesterol (non-HDL-C). The cost-effectiveness of LDL-C, non-HDL-C, and apoB goals has not been established. OBJECTIVE: To determine the relative cost-effectiveness of intensifying LLT for primary prevention based on LDL-C, non-HDL-C, and apoB
3. Zodasiran for cholesterol and triglyceride lowering in patients with hyperlipidemia: final report of phase 1 basket trial.
In a 16-week phase 1 basket trial with a placebo-controlled hyperlipidemia cohort (n=9) plus FH (n=17) and hypertriglyceridemia (n=6), subcutaneous zodasiran reduced serum ANGPTL3 by up to 85% and triglycerides by up to 67% at week 16. No serious treatment-related adverse events or lab signal elevations occurred; effects sustained during a 48-week open-label extension in FH.
Impact: Demonstrates a potent, mechanistically targeted siRNA approach to dyslipidemia with encouraging early safety, opening a path for hard-outcome trials across mixed lipid phenotypes.
Clinical Implications: If replicated in phase 2/3 with outcomes, ANGPTL3 siRNA could expand options for patients with hypertriglyceridemia, mixed dyslipidemia, or statin-intolerant profiles, potentially complementing existing LLT.
Key Findings
- At week 16, serum ANGPTL3 decreased up to 85.4% and triglycerides up to 67.1% across cohorts.
- No serious treatment-related adverse events or elevations in hepatic enzymes, bilirubin, or HbA1c were observed.
- ANGPTL3 suppression was sustained through the 48-week open-label extension in the FH cohort.
Methodological Strengths
- Basket design spanning multiple dyslipidemia phenotypes with a placebo arm in hyperlipidemia
- Extended follow-up in FH cohort demonstrates durability
Limitations
- Small phase 1 sample sizes and short double-blind duration
- Surrogate endpoints without cardiovascular outcome data
Future Directions: Phase 2/3 randomized outcome trials across diverse dyslipidemia populations; head-to-head comparisons with other ANGPTL3/apoC3-targeted therapies and PCSK9-based regimens.
Loss-of-function variants in the gene encoding angiopoietin-like protein 3 (ANGPTL3) are associated with decreased triglyceride and low-density lipoprotein cholesterol levels, as well as with lower cardiovascular risk. Here we describe a 16-week phase 1 trial of zodasiran, an ANGPTL3‑targeting small interfering RNA, in patients on lipid-lowering therapy with either hyperlipidemia (with a placebo control arm) (n = 9; 7 male and 2 female), familial hypercholesterolemia (n = 17; 9 male and 8 female) or